Skip to main content

Combination of F-ASO and Targeted Medical Therapy in Patients With Secundum ASD and Severe PAH

Structural

J Am Coll Cardiol Intv, 13 (17) 2024–2034
Sections

Central Illustration

Abstract

Objectives

This study was conducted to investigate the combined use of fenestrated atrial septal occluder (F-ASO) and targeted medical therapy (TMT) in patients with secundum atrial septal defect (ASD) and severe pulmonary arterial hypertension (PAH).

Background

Treatment of patients with ASD and severe PAH is still challenging.

Methods

After ethical approval was obtained, 56 consecutive patients with ASD with severe PAH were included (7 men, 49 women; median age 50.5 years; mean ASD size 26.9 ± 4.6 mm). After 3 months of TMT, transcatheter closure was performed using F-ASO in patients with ratios of pulmonary to systemic blood flow ≥1.5. TMT was continued post-operatively together with 6 months of dual-antiplatelet therapy. The hemodynamic variables during baseline, TMT alone, and combined treatment with F-ASO were compared.

Results

After only TMT, systolic pulmonary arterial pressure (−14.5 mm Hg; p < 0.001), pulmonary vascular resistance (−3.9 Wood units; p < 0.001), and exercise capacity (+72.0 m; p < 0.001) improved. Ratio of pulmonary to systemic blood flow increased by 0.9 (p < 0.001), with adverse cardiac remodeling (right ventricular dimension +3.5 mm; p < 0.001). Closure with F-ASO (median size 34.0 mm) led to further decrease in systolic pulmonary artery pressure (−6.0 mm Hg; p < 0.001). Follow-up (median duration 10 months) revealed further improvement in exercise capacity (+60.5 m; p < 0.001), with favorable cardiac remodeling (right ventricular dimension −9.9 mm; p < 0.001). In addition, all fenestrations were stable (p = 0.699), with negligible shunt (median ratio of pulmonary to systemic blood flow 1.1) and no complications. One year later, pulmonary artery pressure was normalized in 8 of 19 patients, and PAH recurred in 5 patients after discontinuation of TMT.

Conclusions

In patients with ASD and severe PAH, combination of F-ASO and TMT was a safe and effective procedure. Compared with TMT alone, the combined treatment further improved exercise capacity, with favorable cardiac remodeling.

  • 1. Stout K.K., Daniels C.J., Aboulhosn J.A., et al. "2018 AHA/ACC guideline for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines". J Am Coll Cardiol 2019;73:1494-1563.

    View ArticleGoogle Scholar
  • 2. JS1 Sachweh, Daebritz S.H., Hermanns B., et al. "Hypertensive pulmonary vascular disease in adults with secundum or sinus venosus atrial septal defect". Ann Thorac Surg 2006;81:207-213.

    CrossrefMedlineGoogle Scholar
  • 3. Bradley E.A., Ammash N., Martinez S.C., et al. "“Treat-to-close”: non-repairable ASD-PAH in the adult: results from the North American ASD-PAH (NAAP) Multicenter Registry". Int J Cardiol 2019;291:127-133.

    CrossrefMedlineGoogle Scholar
  • 4. Dimopoulos K., Wort S.J., Gatzoulis M.A. "Pulmonary hypertension related to congenital heart disease: a call for action". Eur Heart J 2014;35:691-700.

    CrossrefMedlineGoogle Scholar
  • 5. Kijima Y., Akagi T., Takaya Y., et al. "Treat and repair strategy in patients with atrial septal defect and significant pulmonary arterial hypertension". Circ J 2016;80:227-234.

    CrossrefMedlineGoogle Scholar
  • 6. Galiè N., Beghetti M., Gatzoulis M.A., et al.for the Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. "Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study". Circulation 2006;114:48-54.

    CrossrefMedlineGoogle Scholar
  • 7. Galiè N., Barberà J.A., Frost A.E., et al.for the AMBITION Investigators. "Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension". N Engl J Med 2015;373:834-844.

    CrossrefMedlineGoogle Scholar
  • 8. Zuckerman W.A., Leaderer D., Rowan C.A., Mituniewicz J.D., Rosenzweig E.B. "Ambrisentan for pulmonary arterial hypertension due to congenital heart disease". Am J Cardiol 2011;107:1381-1385.

    CrossrefMedlineGoogle Scholar
  • 9. Kretschmar O., Sglimbea A., Corti R., et al. "Shunt reduction with a fenestrated Amplatzer device". Catheter Cardiovasc Interv 2010;76:564-571.

    CrossrefMedlineGoogle Scholar
  • 10. Tufaro V., Butera G. "Fenestrated ASD device “angioplasty”: how to adjust a “pop-off” mechanism when needed". Catheter Cardiovasc Interv 2018;92:1329-1333.

    CrossrefMedlineGoogle Scholar
  • 11. Abdelkarim A., Levi D.S., Tran B., Ghobrial J., Aboulhosn J. "Fenestrated transcatheter ASD closure in adults with diastolic dysfunction and/or pulmonary hypertension: case series and review of the literature". Congenit Heart Dis 2016;11:663-671.

    CrossrefMedlineGoogle Scholar
  • 12. Bruch L., Winkelmann A., Sonntag S., et al. "Fenestrated occluders for treatment of ASD in elderly patients with pulmonary hypertension and/or right heart failure". J Interv Cardiol 2008;21:44-49.

    CrossrefMedlineGoogle Scholar
  • 13. Yan C., Li S., Song H., et al. "Off-label use of duct occluder in transcatheter closure of secundum atrial septal defect with no rim to right pulmonary vein". J Thorac Cardiovasc Surg 2019;157:1603-1608.

    CrossrefMedlineGoogle Scholar
  • 14. Yan C., Wang C., Pan X., et al. "Three-dimensional printing assisted transcatheter closure of atrial septal defect with deficient posterior-inferior rim". Catheter Cardiovasc Interv 2018;92:1309-1314.

    CrossrefMedlineGoogle Scholar
  • 15. Yong G., Khairy P., De Guise P., et al. "Pulmonary arterial hypertension in patients with transcatheter closure of secundum atrial septal defects: a longitudinal study". Circ Cardiovasc Interv 2009;2:455-462.

    CrossrefMedlineGoogle Scholar
  • 16. Galiè N., Humbert M., Vachiery J.L., et al.for the ESC Scientific Document Group. "2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)". Eur Heart J 2016;37:67-119.

    CrossrefMedlineGoogle Scholar
  • 17. Pan W., Zhang Y., Guan L., et al. "Usefulness of mean pulmonary artery pressure for predicting outcomes of transcatheter closure of atrial septal defect with pulmonary arterial hypertension". EuroIntervention 2019Jun18[E-pub ahead of print].

    Google Scholar
  • 18. Gabriels C., De Meester P., Pasquet A., et al. "A different view on predictors of pulmonary hypertension in secundum atrial septal defect". Int J Cardiol 2014;176:833-840.

    CrossrefMedlineGoogle Scholar
  • 19. Bradley E.A., Chakinala M., Billadello J.J. "Usefulness of medical therapy for pulmonary hypertension and delayed atrial septal defect closure". Am J Cardiol 2013;112:1471-1476.

    CrossrefMedlineGoogle Scholar
  • 20. D’Alto M., Romeo E., Argiento P., et al. "Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology". Int J Cardiol 2012;155:378-382.

    CrossrefMedlineGoogle Scholar
  • 21. Taniguchi Y., Emoto N., Miyagawa K., et al. "Subsequent shunt closure after targeted medical therapy can be an effective strategy for secundum atrial septal defect with severe pulmonary arterial hypertension: two case reports: strategy for ASD with severe PAH". Heart Vessels 2014;29:282-285.

    CrossrefMedlineGoogle Scholar